AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

Core Insights - Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on developing effective and rapid-acting mental health treatments [2] - The company was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025 [2] - Key products in Atai Beckley's pipeline include BPL-003, VLS-01, and EMP-01, all of which are in Phase 2 clinical development targeting treatment-resistant depression and social anxiety disorder [2] Company Participation - Srinivas Rao, M.D., Ph.D., and Kevin Craig, M.D. will participate in the Jefferies Global Healthcare Conference in London [1] - The format will include a fireside chat and one-on-one investor meetings scheduled for November 20 at 11:30 A.M. GMT [1] - An archived replay of the event will be available on the company's website for up to 90 days [1]